Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 4/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | CEPT1 | Q9Y6K0 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1735102 | 0.81 | RAB9A (0.43) | ESR1ESR2NPC1TP53RAB9A | |
| SCHEMBL1733888 | 0.76 | CEPT1 (0.45) | ESR1ESR2NPC1TP53RAB9A | |
| SCHEMBL30493519 | 0.71 | RAB9A (0.55) | NPC1TP53RAB9ASMN1; SMN2PKM | |
| SCHEMBL29030361 | 0.71 | RAB9A (0.55) | NPC1TP53RAB9ASMN1; SMN2PKM | |
| SCHEMBL3190619 | 0.66 | NPC1 (0.63) | NPC1TP53RAB9ASMN1; SMN2PKM | |
| SCHEMBL1736085 | 0.66 | CEPT1 (0.43) | NPC1RAB9ACEPT1 | |
| SCHEMBL21674269 | 0.63 | NPC1 (0.63) | NPC1TP53RAB9ASMN1; SMN2PKM | |
| SCHEMBL1733936 | 0.63 | CEPT1 (0.58) | TP53SMN1; SMN2CEPT1MAPT | |
| SCHEMBL25955977 | 0.62 | NPC1 (0.33) | NPC1TP53RAB9ASMN1; SMN2PKM | |
| SCHEMBL1733864 | 0.62 | NPC1 (0.53) | ESR1ESR2NPC1TP53RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1954287-B2 | CETP INHIBITORS | MERCK SHARP & DOHME (US) | 2016-02-24 | — | — | EP | disclosed |
| EP-1954287-B1 | CETP INHIBITORS | MERCK SHARP & DOHME (US) | 2011-11-16 | — | — | EP | disclosed |
| US-20110262658-A1 | PROCESS AND DEVICE FOR TREATING THE COATING OF THERMOPLASTIC RESIN CONTAINERS | ZOPPAS MATTEO | 2011-10-27 | — | — | US | disclosed |
| US-20090264405-A1 | Cetp Inhibitors | MERCK SHARP & DOHME LLC | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264405-A1 | Cetp Inhibitors | CETP, APOB, PCSK9 | ESR1 3810/4885ESR2 1535/4885NPC1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.